Pulmonary hypertension (PH) is a severe condition characterized by remodeling and stiffening in the pulmonary vasculature, leading to increased mortality risk, especially when combined with conditions like heart failure or chronic lung disease. Current PH classifications fail to reflect the underlying molecular drivers, leaving significant treatment gaps across different PH groups.

Synhale Therapeutics is developing Telaglenastat, a glutaminase inhibitor, to address the elevated glutaminase activity that drives vascular stiffness, fibrosis, and proliferation in all PH groups. By targeting this fundamental metabolic pathway, Synhale aims to provide a mechanism-driven therapy that addresses the root cause of PH, offering hope to patients with limited options. Telaglenastat has already been dosed in over 800 patients during oncology development and is Phase 2-ready with extensive preclinical data for PH. Synhale's clinical advancement strategy aims to address a significant market opportunity across PH Groups 1-4.

Targets elevated glutaminase activity, a key driver of vascular stiffness, fibrosis, and proliferation in PH.

Aims to address the unmet patient need across PH Groups 1-4, including pulmonary arterial hypertension, PH linked to heart failure, and PH linked to chronic lung disease.

Phase 2-ready asset with prior human clinical experience in over 800 patients.

Extensive preclinical data supporting its use in pulmonary hypertension.

The primary target audience includes patients suffering from pulmonary hypertension across Groups 1-4, as well as healthcare providers specializing in pulmonary and cardiovascular diseases.